- Home
- MIST vs TARA Comparison
MIST vs TARA Comparison
Compare MIST & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIST | TARA |
|---|---|---|
| Founded | 2003 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.9M | 159.6M |
| IPO Year | 2019 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MIST | TARA |
|---|---|---|
| Price | $0.78 | $2.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $5.86 | ★ $25.71 |
| AVG Volume (30 Days) | ★ 1.4M | 1.3M |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | $147.62 | N/A |
| Revenue Next Year | $476.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $2.75 |
| 52 Week High | $3.06 | $7.82 |
Technical Indicators
Market Signals| Indicator | MIST | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 31.05 | 17.98 |
| Support Level | $0.75 | N/A |
| Resistance Level | $1.42 | $4.13 |
| Average True Range (ATR) | 0.06 | 0.24 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 13.44 | 4.00 |
Price Performance
Historical ComparisonAbout MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.